Separate the small topical human report, hair-follicle experiments and commercial research listings before transferring a hair-growth claim.
Zinc-thymulin has a published human hair-loss report, but it does not establish a reliable treatment or validate commercial research vials. The useful question is which material, outcome and route each claim actually concerns.
Sources and current site listings were checked November 11, 2026. This is an evidence guide, not a preparation or treatment protocol.
Vickers's 2017 report followed 18 adults using a 0.0005% zinc-thymulin scalp spray for 4–10 months, without a control group.
| Measurement | Reported result |
|---|---|
| Overall photographic score | Full group: P=0.07; 11-person subgroup treated at least six months: P=0.045. |
| Close-up hair proportions, 10 people | Terminal: P=0.86; intermediate: P=0.02. |
| Safety | One brief redness episode attributed to the buffer. Three also used minoxidil and/or finasteride. |
| Commercial interest | Author disclosed a financial interest and patent application. |
The full-group photographic result and terminal-hair proportion were not statistically significant. Intermediate-hair changes cannot establish increased thick, terminal hair or scalp coverage. The subgroup result does not establish a six-month treatment rule. These small, uncontrolled observations cannot establish uncommon risks or interaction safety.
An earlier patent application describing original follicle experiments examined human scalp follicles outside the body. It measured shaft elongation, pigmentation and hair-cycle stages separately. Its examples describe variation between tissue donors and no significant difference in elongation in one assay. Thymulin-treated follicles could remain in anagen, the growth phase, without demonstrating consistently greater shaft production.
That distinction matters when a headline promises that a peptide “keeps hair growing.” Ask which measurement supports those words. A change in cycle stage, pigment, shaft length, photographic rating and scalp hair density are separate outcomes. A patent's proposed treatment claims do not turn its laboratory examples into a clinical trial. These experiments also do not establish that thymulin makes hair loss worse in people.
The frequently cited 2012 research-letter record concerns human hair follicles in organ culture. Its PubMed record has no abstract; it should not be used alone to supply an effect size or a consumer regimen.
A shared name does not answer the formulation question. Record exactly what is being offered, then ask for evidence matching that material and intended route.
| Documentation question | Why ask it? |
|---|---|
| What is the peptide identity and zinc-binding evidence? | A name or total zinc result alone does not demonstrate the identity of the complete preparation. |
| What finished formulation was tested? | Peptide identity, concentration, vehicle and product stability are separate checks. |
| What route does the evidence concern? | A scalp preparation does not establish an injection's effects or safety. |
| What does the lot report measure? | Analytical identity and purity do not establish clinical benefit. Use the COA guide to inspect the actual methods and limits. |
The existing thymulin catalog page links to NextGenPeps's Thymulin listing. That is a research-product listing, not a verified match to the studied scalp preparation. Biomogging may earn a commission from qualifying purchases through affiliate links. A catalog link is not an endorsement for treating hair loss.
For a treatment decision, take the claim and original source to a dermatologist. The existing hair-treatment evidence and review guide provides a separate starting point for discussing established options and assessment timing.
Powered by BTST